GE Healthcare Considers Selling China Unit Amidst Vaccine Panel Shift

GE Healthcare, a major U.S. medical device manufacturer, is contemplating the sale of its China unit. According to sources familiar with the matter, the company is working with advisers to explore various options, including a potential sale, partnering within China, or selling a stake in the unit. These discussions, kept confidential, represent strategic maneuvering in an increasingly complex global market.

In a significant policy shift, a U.S. vaccine advisory panel under Health Secretary Robert F. Kennedy Jr. has rescinded its broad support for COVID-19 vaccines. The panel now recommends that the shots be administered based on individualized clinical decision-making in consultation with healthcare providers. This move reflects deep divides in U.S. immunization policy as the panel seeks to balance scientific evidence with public concerns about vaccine safety.

The dual developments in healthcare reflect broader themes of strategic realignment and policy evolution, as companies and governments navigate post-pandemic realities. Both stories highlight the complex interplay of market dynamics, healthcare regulation, and public health strategy amidst a continually shifting landscape.

(With inputs from agencies.)